Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06328673 · ClinicalTrials.gov registry record · Phase 1
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by D2M Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 2
- Study locations
NCT06328673: Active Phase 1 study of Advanced Solid Tumor, sponsored by D2M Biotherapeutics.
NCT06328673 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by D2M Biotherapeutics. The registered enrollment target is 160 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06328673, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by D2M Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab?? Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to measure whether DM-919 will have the effect on tumors.
Primary Outcome
TEAE is defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study drug.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG DM919
Study Locations (2)
Texas
- NEXT Oncology - San Antonio
Other
- The Cancer Institute and Hospital, Chinese Academy of Medical Sciences(CAMS) - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 1 |
What the registry record for NCT06328673 still lists
NCT06328673 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06328673 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06328673 about?
NCT06328673 is a clinical study titled "A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors". The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively wi...
What is the current status of trial NCT06328673?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2024-04-09. Estimated completion is 2026-03-01.
What conditions does trial NCT06328673 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06328673?
The interventions under investigation include: Pembrolizumab (DRUG), DM919 (DRUG).
Who is sponsoring clinical trial NCT06328673?
This trial is sponsored by D2M Biotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06328673 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06328673's enrollment target sits among peer trials
160 78th of 189 higher than 111 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI